CGON: CG Oncology Inc Kompaniya qiymatining sof foydaga nisbati

CG Oncology Inc - CGON emitenti grafik logotipi

CG Oncology, Inc. (CGON) o'zining tadqiqot va ishlanmalar (R&D) imkoniyatlarini o'simtalarning immunoterapiyasi uchun virusli dori vositalarini ishlab chiqishga yo'naltirgan yetakchi biotexnologiya kashfiyotchisidir. Kompaniyaning choraklik P/E koeffitsiyenti foydaga nisbatan bozor qiymatining dinamikasini aks ettiradi, -31.30 esa ushbu parametrning joriy holatini ifodalaydi. Rivojlanish strategiyasi qovuq saratoni davolash bo'yicha tibbiyot markazlari bilan sinergiyaga tayanadi va FDA qo'llab-quvvatlashi bilan bir qatorda patentlar orqali himoyalangan.

Narx-foyda koeffitsiyenti: CG Oncology, Inc. (CGON) 14.11.2024 - 17.11.2026 uchun

CG Oncology Inc (CGON) boʻyicha keng qamrovli koʻrsatkichlar kesimi va tahlil

- bozor kapitallashuvi haqida ma'lumot:
Kompaniyaning jamlanma tahlili:CGON CG Oncology
CG Oncology yetakchi tovari

CG Oncology, Inc. (CGON) barqarorligi onkologik klinik sinovlar natijalariga asoslangan bo'lib, ular bozorning sikllilikidan mustaqil qolmoqda. Kompaniyaning joriy P/E koeffitsiyentini tahlil qilish orqali investor bozor kapitalizatsiyasi va sof foyda o'rtasidagi bog'liqlikni ko'rishi mumkin, bu esa haqiqiy daromadlar nisbatidagi narx premiumini baholash va aktivga kirishning adolatli nuqtasini aniqlash imkonini beradi.

Muhim raqobatchilar

ONC: Kompaniya qiymatining sof foydaga nisbati|Narx-foyda koeffitsiyenti HALO (Halozyme Inc.)|RVMD (RevMed) - Kompaniya qiymatining sof foydaga nisbati|P/E multiplikatori AAPG (ascentage.com)|URGN - Narx-foyda koeffitsiyenti|BCAX: Narx-foyda koeffitsiyenti|PSNL - P/E multiplikatori|Erasca Corp (ERAS) - Narxning foydaga nisbati|Delcath - Kompaniya qiymatining sof foydaga nisbati|YMAB (Y-mAbs Therapeutics Inc) - P/E multiplikatori|Kapitalizatsiyaning foydaga nisbati Aura Biosciences, Inc. AURA|P/E multiplikatori CADL|P/E multiplikatori Accuray (ARAY)|Narxning foydaga nisbati SELLAS Life Sciences Group Inc. SLS|ACTU - Narx-foyda koeffitsiyenti|CTOR: Narx-foyda koeffitsiyenti|Kompaniya qiymatining sof foydaga nisbati HURA (TuHURA Biosciences Inc.)|TARA (Protara Therapeutics) - Narx-foyda koeffitsiyenti|Kapitalizatsiyaning foydaga nisbati Fate Therapeutics Corp (FATE)|Narx-foyda koeffitsiyenti WHWK|Narx-foyda multiplikatori TCRX (TScan Therapeutics, Inc.)|P/E multiplikatori CSBR|XBIT - Kapitalizatsiyaning foydaga nisbati|CEL-SCI Corporation - Narx-foyda koeffitsiyenti|Kompaniya qiymatining sof foydaga nisbati OSTX|radiopharmtheranostics.com - P/E multiplikatori|ARTV: Narxning foydaga nisbati|ANL (adlainortye.com) - Narx-foyda koeffitsiyenti|VERU - Biznesning o‘zini qoplash muddati|TPST (Tempest Therapeutics, Inc.) - P/E multiplikatori|P/E multiplikatori xiliotx.com|Narxning foydaga nisbati Enochian BioSciences (RENB)|Narxning foydaga nisbati MURA (Mural Oncology PLC)|Narxning foydaga nisbati Kairos Pharma Ltd KAPA|P/E multiplikatori OnKure Therapeutics Inc OKUR|CytoMed Therapeutics - P/E multiplikatori|Biznesning o‘zini qoplash muddati Curis CRIS|APLM: P/E multiplikatori|Narx-foyda koeffitsiyenti Tharimmune, Inc.|ADVB (Advanced Biomed) - P/E multiplikatori|Genprex - Kapitalizatsiyaning sof foydaga nisbati|Narxning foydaga nisbati calidibio.com (CLDI)|SBFM (Sunshine Biopharma Inc.) - Kompaniya qiymatining sof foydaga nisbati|P/E multiplikatori XBIO (Xenetic Biosciences)|Salarius Pharmaceuticals (SLRX) - Kapitalizatsiyaning foydaga nisbati|PPBT: Narx-foyda koeffitsiyenti|Kompaniya qiymatining sof foydaga nisbati AONC (American Oncology Network, Inc.)|BeOne Medicines (BGNE) - Narxning foydaga nisbati|Checkpoint Therapeutics, Inc (CKPT) - P/E multiplikatori|Narxning foydaga nisbati Elevation Oncology, Inc.|ICAD: Kompaniya qiymatining sof foydaga nisbati|Narxning foydaga nisbati ikenaoncology.com (IKNA)|Narxning foydaga nisbati NTBL (Notable Labs, Ltd.)|P/E multiplikatori VIRX (viracta.com)|MOR - Narx-foyda koeffitsiyenti|NAYA - Narxning foydaga nisbati|Kapitalizatsiyaning sof foydaga nisbati AAPGV